Masaki Ri1, Takahiko Yasuda2, Hiroshi Handa3, Tadao Ishida4, Hirohiko Shibayama5, Masahiro Abe6, Takashi Kanamori1,2, Masashi Sanada2, Hiroyoshi Hattori2, Dai Nishijima2, Hiroki Kurahashi7, Yuichi Shiraishi8, Matsuo Yamamoto2, Akiko Saito2, Satoru Miyano9, Seishi Ogawa10, Keizo Horibe2, Shinsuke Iida1 (1.Department of Hematology and Oncology, Nagoya City University, Nagoya, Japan, 2.Clinical Research Center, Nagoya Medical Center, Nagoya, Japan, 3.Department of Hematology, Gunma University, Maebashi, Japan, 4.Department of Hematology, Japanese Red Cross Medical Center, 5.Department of Hematology and Oncology, Osaka University, Osaka, Japan, 6.Department of Hematology, Endocrinology and Metabolism, Tokushima University, Tokushima, Japan, 7.Department of Molecular Genetics, Fujita Health University, Toyoake, Japan, 8.Cancer Genomics and Advanced Therapeutics, National Cancer Center, Tokyo, Japan, 9.Human Genome Center, University of Tokyo, Tokyo, Japan, 10.Pathology and Tumor Biology, Kyoto University, Kyoto, Japan)
Session information
Oral Session
Oral Session 3-15A Multiple Myeloma: Clinical (MRD/Infection)
Sun. Oct 13, 2019 9:00 AM - 10:00 AM No.15 (Tokyo International Forum, 7F G701)
Chair: Hiroyuki Takamatsu (Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University)
Takeshi Yoroidaka1, Hiroyuki Takamatsu1, Takeshi Yamashita2, Ryoichi Murata2, Kyoko Yoshihara4, Satoshi Yoshihara4, Mikio Ueda2, Shinji Nakao1, Kosei Matsue3 (1.Hematol., Kanazawa Univ., Kanazawa, Japan, 2.Keiju Kanazawa Hospital, Kanazawa, Japan, 3.Kameda Medical Center, Kamogawa, Japan, 4.Hyogo College of Medicine, Nishinomiya, Japan)
Hiroyuki Takamatsu1, Takeshi Yoroidaka1, Takeshi Yamashita2, Ryoichi Murata2, Mikio Ueda2, Shinji Nakao1, Kosei Matsue3 (1.Hematol., Kanazawa Univ., Kanazawa, Japan, 2.Keiju Kanazawa Hospital, Kanazawa, Japan, 3.Kameda Medical Center, Kamogawa, Japan)
Yoshiaki Abe, Toshiki Terao, Kosei Matsue (Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan)
Chun-Kuang Tsai1, Yao-Chung Liu1,4, Chiu-Mei Yeh1, Kang-Lung Lee2,3, Po-Shen Ko1,4, Hao-Yuan Wang1,4, Sheng-Hsuan Chien4,5, Liang-Tsai Hsiao1,4, Jyh-Pyng Gau1,4, Chia-Jen Liu1,4 (1.Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2.School of Medicine, National Yang-Ming University, Taipei, Taiwan, 3.Department of Radiology, Taipei Veterans General Hospital, Taipei City, Taipei, Taiwan, 4.Faculty of Medicine National Yang-Ming University, Taipei, Taiwan, Taiwan, 5.Division of Transfusion Medicine, Taipei Veterans General Hospital, Taipei, Taiwan)
Sumeet P Mirgh1,2, Sweta Kothari2, Rohan Halder2, Manoranjan Mahapatra2, Tulika Seth2, Rishi Dhawan2, HaraPrasad Pati2, Seema Tyagi2, Renu Saxena2 (1.Hematology, Rajiv Gandhi Cancer Institute, New Delhi, Republic of India, 2.Dept of Hematology, All India Institute of Medical Sciences, New Delhi, Republic of India)